DYRK2

Across TCGA pan-cancer cohorts, DYRK2 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated DYRK2 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher DYRK2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DYRK2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, UCEC, and ACC are the cancer types where DYRK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.226	0.925	<.001	36	view →
UCEC	DFS	Median	All	0.962	0.824	.007	30	view →
ACC	DFS	Median	All	0.120	0.772	<.001	21	view →
LUAD	OS	Median	All	0.090	0.788	<.001	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SARC	DFS	Median	All	0.135	0.613	.001	12	view →
BLCA	DFS	Median	All	0.507	0.616	<.001	10	view →
KIRP	OS	Median	All	0.270	0.904	<.001	6	view →
LIHC	DFS	Median	All	0.263	0.559	.027	6	view →
SCLC	OS	Median	All	0.219	0.650	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

DYRK2–BRCA (OS)

Open the BRCA breakdown →